FIELD: pharmaceutics.
SUBSTANCE: invention relates to a compound of formula 1 or a pharmaceutically acceptable salt thereof, which are G-protein coupled receptor 6 (GPR6) modulators. Invention also relates to a pharmaceutical composition, a kit, a dosage form containing said compound, a method of treating using the same and using it for preparing a drug for treating a disease, disorder or condition associated with GPR6.
EFFECT: tetrahydropyridopyrazine GPR6 modulators are disclosed.
40 cl, 2 tbl, 1 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHROMON OXIME NEW DERIVATIVE AND ITS USE AS ALLOSTERIC MODULATOR OF METABOTROPIC GLUTAMATE RECEPTORS | 2015 |
|
RU2672569C2 |
| APPLICATION OF 2-(2-NITRO-4-TRIFLUORMETHYLBENZOYL)-1,3-CYCLOHEXANDIONE IN TREATMENT OF PARKINSON'S DISEASE | 2006 |
|
RU2420272C2 |
| LEVODOPA MESYLATE PRODRUG, COMPOSITION THEREOF AND USE | 2006 |
|
RU2429223C2 |
| PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF LEVODOPA PRODRUG AND METHODS OF USING | 2010 |
|
RU2537137C2 |
| METHODS OF PARKINSON'S DISEASE TREATMENT | 2004 |
|
RU2342929C2 |
| ORGANIC COMPOUNDS | 2017 |
|
RU2733975C2 |
| SUBSTITUTED TETRAHYDROISOQUINOLINE DERIVATIVE AS POSITIVE ALLOSTERIC MODULATOR D1 | 2020 |
|
RU2824581C2 |
| CARBIDOPA AND L-DOPA PRODRUGS AND USE THEREOF FOR TREATING PARKINSON'S DISEASE | 2015 |
|
RU2743347C2 |
| METHOD FOR TREATMENT OF PARKINSON'S DISEASE | 2014 |
|
RU2677278C2 |
| LEVODOP PRODRUGS, BASED ON THEM COMPOSITIONS AND THEIR APPLICATION | 2005 |
|
RU2365580C2 |
